REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT dated byCollaboration and License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”) and is entered into by and between:
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), effective as of November 9, 2017 (the “Effective Date”), is made by and between CureVac AG, a German stock corporation organized under the laws of Germany, having its principal place of business at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”), and CRISPR Therapeutics AG, a Swiss corporation organized under the laws of Switzerland (“CRISPR”), having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland. CureVac and CRISPR are each sometimes referred to herein as a “Party” and collectively as the “Parties.”
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. DATED: 15 February 2019 FRAMEWORK PARTNERING...Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • England and Wales
Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc. DatedDevelopment and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This Development and Option Agreement (this "Agreement"), dated as of 1 January 2018 (the "Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany ("CureVac"), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive # 200, San Diego, CA 92121, USA ("Arcturus"). Each of CureVac and Arcturus may be referred to herein as a "Party" or together as the "Parties".
EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT - by and between - CUREVAC GMBH - and - BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUGUST 21, 2014Exclusive Collaboration and License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
Exhibit 4.5B Description of CureVac's License Agreements with the Ludwig Institute for Cancer Research, the University of Zurich and Geneart AG
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.Development and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT (this “Third Amendment”) to the Development and Option Agreement dated January 1, 2018 (the “Original Agreement”), is entered into by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”; each of CureVac and Arcturus individually a “Party” and together the “Parties”) as of July 26, 2019 (the “Third Amendment Date”).
EXECUTION COPY SIDE AGREEMENT AND AMENDMENT NUMBER ONE to the DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
THIS SIDE AGREEMENT AND AMENDMENT (“Amendment Agreement”) to the DEVELOPMENT AND OPTION AGREEMENT is entered into effective as of December I, 2016 (the “Amendment One Date”), by and between ACUITAS THERAPEUTICS INC., with offices at 2714 West 31st Avenue, Vancouver, British Columbia, V6L 2Al, Canada (“Acuitas”), and CUREVAC AG, a company incorporated in Germany whose registered office is at Paul-Ehrlich-Straf3e 15, 72076 Tübingen, Germany (“CureVac”).
AMENDMENT NO. 1 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
WHEREAS, the Parties entered into that certain Exclusive Collaboration and License Agreement effective as of August 21, 2014 ("Agreement");
Development and Option Agreement by and between CureVac AG and Acuitas Therapeutics Inc. dated APRIL 29, 2016License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • England and Wales
This Development and Option Agreement (this “Agreement”), dated as of April 29, 2016 (the “Effective Date”), is made by and between CureVac AG, a German stock corporation with offices at Paul- Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of CureVac and Acuitas may be referred to herein as a “Party” or together as the “Parties.”
ContractCureVac B.V. • June 22nd, 2020 • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
ContractCureVac B.V. • June 22nd, 2020 • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
THIS RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT (this “Amendment”), dated as of September 28, 2018 (the “Amendment Restatement Date”), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“CureVac”), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive #200, San Diego, CA 92121, USA (“Arcturus”). Each of CureVac and Arcturus may be referred to herein as a “Party” or together as the “Parties”.
ContractCureVac B.V. • June 22nd, 2020 • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
Convertible LoanConvertible Loan • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
For the purposes of the financing of the business of the Borrower, the Lender has granted the Borrower a loan in an amount of EUR 50 million (“Convertible Loan I”) by agreement dated 3rd May 2019 (“Agreement regarding a Convertible Loan”). The Convertible Loan I has already been disbursed completely.
ContractCureVac B.V. • June 22nd, 2020 • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
ContractCureVac B.V. • June 22nd, 2020 • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
